From the Editor

May 01, 2006
Pharmaceutical Executive
Where is pharma going? Toward more science, and more political pressure on science. Toward greater patient responsibility—and more regulation-by-lawsuit. And forward. Let's not forget about forward.
Apr 01, 2006
Pharmaceutical Executive
Safety advocates want to make it tougher for new drugs to win FDA approval. Consumer advocates want to make it legal to import drugs from abroad. Put those ideas together, and what have you got?
Mar 01, 2006
Pharmaceutical Executive
The newspapers seem shocked to learn that scientific journals occasionally publish things that aren't true. Where have they been?
Feb 01, 2006
Pharmaceutical Executive
Is the public ready for an exciting thriller about terrorism, drug counterfeiting, valiant FDA agents, and glamorous women who invite pharma CEOs to come up and look at their drug patents? Sure. Maybe someone should write one.
Jan 01, 2006
Pharmaceutical Executive
Witnessing an industry's wild ride is perhaps the best reason to work for a business magazine. You've given us 25 years of excitement. And we plan to pay you back.
Dec 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
The public is focused on drug safety, but the real issue isn't approval standards. It's the way drugs expand to unapproved new indications. Are you listening, Acomplia?
Nov 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Leo H. Sternbach's death feels like the end of an era, a time when the new drugs came easily and it was possible to have a huge impact on patients, then turn around and do it again.
Oct 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
In an opinion piece in the September 8 New England Journal of Medicine, Harvard medical professor and long-time industry critic Jerry Avorn takes a whack at FDA, accusing the agency of practicing a level of science that wouldn’t pass muster anywhere else in research—science that’s only "good enough for government work.";
Sep 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
My doctor and I have two different visions of an avian influenza pandemic. She's picturing regular flu season, but worse. I'm imagining 1918. Does the conflict sound familiar?
Aug 01, 2005
Pharmaceutical Executive
With patients who suffer from poverty, lack of education, and disease, it is incredibly easy to do damage through a marketing tactic that might be acceptable for another group.
native1_300x100
lorem ipsum